Company intelligence / Profile preview

Navire Solide

Palo Alto, California, United Statesfr.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

Navire Pharma’s lead program BBP‑398, a SHP2 inhibitor, has entered Phase 1 clinical trials for patients with advanced or metastatic solid tumors driven by MAPK pathway mutations. The primary objective of the ongoing study is to evaluate safety; secondary objectives include preliminary anti-tumor activity. As of the latest updates, no pivotal efficacy results have been published.

Therapeutic areas: Oncology
Modalities: Small moleculeMolecular glue therapy
Industry: Biotech

Partnerships

Bristol Myers Squibb (exclusive license for global development/commercialization of BBP‑398 outside Asia)LianBio (strategic collaboration for Asian markets)Amgen (clinical collaboration to evaluate combination with sotorasib/LUMAKRAS®)

Beyond the preview

Go deeper on Navire Solide.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navire Solide.

Explore the full profile